Sample reduction strategies such as sample pooling can significantly increase the capacity and throughput of a laboratory. 1 In this context, we wanted to discuss the application of this analytical strategy in the analysis of synthetic cannabinoids and new designer drugs in the forensic toxicology.
The rapid development of synthetic cannabinoids and new designer drugs, which in fact are simple derivatives of amphetamine, tryptamine, piperazine and cathinone, became a real analytical problem in recent years. This is the reason why different analytical methods which cover a wide range of new drugs have been developed and applied. [2] [3] [4] [5] [6] [7] [8] However, these methods need to be upgraded constantly, since new important substances are identified all the time. Among published methods, liquid chromatographytandem mass spectrometry (LC-MS/MS) is mostly used because its application is often the only way to confirm drug consumption. 9 The more drugs that are monitored with an LC-MS/MS method, the more mass transitions have to be included (target and qualifier mass transition for each drug in a forensic method), and therefore the more data are collected for each sample during MS/MS acquisition. This fact, together with the amount of samples, makes the sample preparation and data evaluation very time consuming. Moreover, the prevalence of synthetic cannabinoids/new designer drugs consumption in forensic cases is still not well explored. 10 On the basis of analyses performed for the purpose of synthetic cannabinoids and new designer drugs concentration monitoring in human serum of patients monitored by therapy centres and forensic psychiatric centres in Lower Saxony (n > 1000), we can classify the prevalence as low as <3%. Thus, the performed analyses are predominantly negative for the investigated drugs.
The low prevalence of synthetic cannabinoids and new designer drugs among patients of therapy centres and forensic psychiatric centres opens a way to work more cost-effectively by the application of sample pooling. In this two-step testing strategy, samples from a number of patients are aggregated into a single sample (pool), which is then tested for drugs of interest in the first analytical step. Samples which belong to a negative pool can be defined as negative, and samples in positive pools have to be analysed individually in the second analytical step. This strategy is more cost-effective, as it reduces sample preparation time (since serum pooling is quite fast and easy) and especially the time of manual data evaluation. Further, the capacity of the LC-MS/MS system used can be expanded for other analyses performed in the laboratory, since in the end, fewer samples are analysed when the serum pooling strategy is applied. A disadvantage of the sample pooling method in forensic toxicology is that the sample is diluted by the pooling step. However, it is possible to compensate for this disadvantage by applying sensitive analytical methods such as those presented earlier with a limit of detection of 0.001-0.022 ng/mL for synthetic cannabinoids and of 0.007-0.440 ng/mL for other new designer drugs. 8 In our laboratory, we applied the serum pooling strategy together with a sensitive LC-MS/MS analytical method to analyse samples (n > 100) sent by therapy centres and forensic psychiatric centres in Lower Saxony. To prove the applicability of the pooling strategy, each sample was analysed both individually (500 mL serum was used) and in a pool containing five samples (5 Â 100 mL serum was used). The achieved results revealed conformity of these two approaches, since the same drugs were found by the application of the pooling strategy. If we consider a sample number of 100 and assume a prevalence of 3%, we can expect three samples with synthetic cannabinoids/new designer drugs among this sample group. The rest (n ¼ 97 samples) is negative for the drugs investigated. By applying the sample pooling strategy on the basis of pools consisting of five samples, in the worst-case scenario, we would have to analyse and evaluate 35 samples (if every positive sample is in a different pool); in the best-case scenario, we would have to analyse and evaluate 25 samples (if every positive sample is in the same pool). The traditional method requires every sample (n ¼ 100) to be analysed individually. To the best of our knowledge, this is the first time the applicability of the sample pooling strategy has been discussed for the analysis of synthetic cannabinoids and new designer drugs. Our preliminary study demonstrates that the sample pooling strategy is an interesting option to analyse these drugs on the basis of sensitive LC-MS/MS analytical methods. In future, the number of samples used in a pool should be optimised to achieve the highest possible performance.
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